Condition

Hormone Receptor Positive Breast Cancer

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11
Recruiting3
Common interventions25
Lead sponsors shown11
Advertisement

Clinical trials

11 shown
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)NCT07222215 · 2026-01-16
RECRUITING
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01
RECRUITING
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)NCT07646171 · 2022-09-01
RECRUITING
Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine TherapyNCT07759947 · 2027-02-01
NOT_YET_RECRUITING
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerNCT04569747 · 2021-01-11
ACTIVE_NOT_RECRUITING
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 InhibitorNCT03854903 · 2019-04-01
COMPLETED
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)NCT03401385 · 2018-01-31
ACTIVE_NOT_RECRUITING
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDONCT03227328 · 2017-08-02
COMPLETED
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerNCT02675231 · 2016-05-23
COMPLETED
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerNCT01698918 · 2013-03-07
COMPLETED
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.NCT01602380 · 2012-10-17
COMPLETED

Common interventions

Trial status mix

COMPLETED5
RECRUITING3
ACTIVE_NOT_RECRUITING2
NOT_YET_RECRUITING1

Phase mix

PHASE25
PHASE12
NA1
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.